Cilnidipine inhibits the sympathetic nerve activity and improves baroreflex sensitivity in patients with hypertension

Clinical and Experimental Hypertension

Volumn 31, Issue 3, 2009, Pages 241-249

  Kishi, Takuya ^a   Hirooka, Yoshitaka ^a   Konno, Satomi ^a   Sunagawa, Kenji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Baroreflex sensitivity; Hypertension; N type calcium channels blocker; Sympathetic nerve activity

Indexed keywords

CILNIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE;

ADRENERGIC TRANSMISSION; ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE VARIABILITY; CHOLINERGIC TRANSMISSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEART RATE VARIABILITY; HUMAN; LABORATORY TEST; MALE; MONOTHERAPY; PRESSORECEPTOR REFLEX; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ADRENERGIC SYSTEM; BLOOD PRESSURE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; DOSE RESPONSE; HEART RATE; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; BAROREFLEX; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PARASYMPATHETIC NERVOUS SYSTEM; PROSPECTIVE STUDIES; SYMPATHETIC NERVOUS SYSTEM;

EID: 67649997687     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960902822492     Document Type: Article

References (33)

1. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until March 2003. pertens3;21:1055-1076.
2. Yoshimoto R, Hashiguchi Y, Dohmoto H, Hosono M, Iida H, Fujiyoshi T, Ikeda K, Hayashi Y. Effects of a new dihydropyridine derivative, FRC-8653, on blood pressure in conscious spontaneously hypertensive rats. armacobio Dyn2;15:25-32.
3. Tominaga M, Phya Y, Tsukashima A, Kobayashi K, Takata Y, Koga T, Yamashita Y, Fujishima Y, Fujishima M. Ambulatory blood pressure monitoring in patients with essential hypertension treated with a new calcium antagonist, cilnidipine. Cardiovasc Drugs Ther 1997;11:43-48.
4. Hosono M, Fujii S, Hiruma T, Watanabe K, Hayashi Y, Ohnishi H, Takata Y, Kato H. Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Jpn J Pharmacol 1995;69:127-134.
5. Oike M, Inoue Y, Kitamura K, Kuriyama H. Dual action of FRC8653, a novel dihydropyridine derivative, on the Ba2+ current recorded from the rabbit artery. Circ Res 1990;57:993-1006.
6. Fujii S, Kameyama K, Hosono M, Hayashi Y, Kitamura K. Effect of cilnidipine, a new dihidropyrydine Ca++ channel antagonist, on N-type Ca++ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1997;280:1184-1191.
7. Uneyama H, Takahara A, Dohmoto H, Yoshimoto R, Inoue K, Akaike N. Blockade of N-type Ca++ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurons. Br J Pharmacol 1997;122:37-42.
8. Mancia G, Parati G, Castiglioni P, Di Rienzo M. Effect of sinoaortic devervation on frequency-domain estimates of baroreflex sensitivity in conscious cats. Am J Physiol 1999;276:H1987-H1993.
9. Laude D, Elghozi JL, Girard A, Bellard E, Bouhaddi M, Castiglioni P, Cerutti C, Cividjian A, Di Rienzo M, Fortrat JO, Janssen B, Karemaker JM, Leftheriotis G, Parati G, Persson PB, Porta A, Quintin L, Regnard J, Rudiger H, Stauss HM. Comparison of various techniques used to estimate spontaneous baroreflex sensitivity. Am J Physiol 2004;286:R226-R231.
10. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical ise. Eur Heart J 1996;17:354-381.
11. Lucini D, Meta GS, Malliani A, Pagani M. Impairment in cardiac autonomic regulation preceding arterial hypertension in humans: insights from spectral analysis of beat-by-beat cardiovascular variability. Circulation 2002;106:2673-2679.
12. Radaelli A, Perlangeli S, Cerutti MC, Mircoli L, Mori I, Boselli K, Bonaita M, Terzoli L, Candotti G, SIgnorini G, Ferrari AU. Altered blood pressure variability in patients with congestive heart failure. J Hypertens 1999;17:1905-1910.
13. Castiglioni P, Di Rienzo M, Veicsteinas A, Parati G, Merati G. Mechanisms of blood pressure and heart rate variability: an insight from low-level paraplegia. Am J Physiol 2007;292: R1502-R1509.
14. Latinen T, Hartikainen J, Vanninen E, Niskanen L, Geelen G, Lansimies E. Age and gender dependency of baroreflex sensitivity in healthy subjects. J Appl Physiol 1998;84:576-583.
15. Mortara A, La Rovere MT, Pinna GD, Prpa A, Maestri R, Fedo O, Pozzoli M, Opasich C, Tavazzi L. Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications. Circulation 1997;96:3450-3458.
16. Farrell TG, Odemuyiwa O, Bashir Y, Gripps TR, Malik M, Ward DE, Camm AJ. Prognostic value of baroreflex sensitivity testing after acute myocardial infarction. Br Heart J 1992;67: 129-137.
17. Hesse C, Charkoudian N, Liu Z, Joyner MJ, Eisenach JH. Baroreflex sensitivity inversely correlates with ambulatory blood pressure in healthy normotensive humans. Hypertension 2007;50: 41-46.
18. Imholz BP, Wielong W, Langewouters GJ, van Montfrans GA. Continuous finger arterial pressure: utility in the cardiovascular laboratory. Clin Auton Res 1991;l1:43-53.
19. Imholz BP, Wieling W, van Montfrans GA, Wesseling KH. Fifteen years experience with finger arterial pressure monitoring: assessment of the technology. Cardiovasc Res 1998;38:605-616.
20. Waki H, Kasparov S, Wong LF, Murphy D, Shimizu T, Paton JFR. Chronic inhibition of eNOS activity in nucleus tractus solitarii enhances baroreceptor reflex in conscious rats. J Physiol 2003;546:233-242.
21. Waki H, Katahira K, Polson JW, Kasparov S, Murphy D, Paton JFR. Automation of analysis of cardiovascular autonomic function from chronic measurements of arterial pressure in conscious rats. Exp Physiol. 2006;91:201-213.
22. Gillman MW, Kannel WB, Belanger A, D'Agostuno RB. Influence of heart rate on mortality among patients with hypertension: the Framingham Study. Am Heart J 1993;125:1148-1154.
23. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
24. Psaty BM, Heckbert SR, Koepsell TD. The risk of myocardial infarction associated with antihy-pertensive drug therapies. JAMA 1995;274:620-625.
25. Johnson P, Shore A, Potter J, Panerai R, James M. Baroreflex sensitivity measured by spectral and sequence analysis in cerebrovascular disease. Clin Auton Res 2006;16:270-275.
26. Kishi T, Hirooka Y, Kimura Y, Sakai K, Ito K, Shimokawa H, Takeshita A. Overexpression of eNOS in RVLM improves impaired baroreflex control of heart rate in SHRSP. Hypertension 2003;41:255-260.
27. Eguchi K, Tomizawa H, Ishikawa J, Hoshide S, Pickering TG, Shimada K, Kario K. Factors associated with baroreflex sensitivity: associated with morning blood pressure. Hypertens Res 2007;30:723-728.
28. Milan A, Caserta MA, Del Colle S, Dematteis A, Morello F, Rabbia F, Mulatero P, Pandian NG, Veglio F. Baroreflex sensitivity correlates with left ventricular morphology and diastolic function in essential hypertension. J Hypertens 2007;25:1655-1664.
29. Eguchi K, Tomizawa H, Ishikawa J, Hoshide S, Fukuda T, Numao T, Shimada K, Kario K. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure. J Cardiovasc Pharmacol 2007;49:394-400.
30. Yamagishi T. Beneficial effect of cilnidipine on morning hypertension and white-coat effect in patients with essential hypertension. Hypertens Res 2006;29:339-344.
31. Sakaki T, Naruse H, Masai M. Cilnidipine as an agent to lower blood pressure without sympathetic nervous activation as demonstrated by iodine-123 metaiodobenzyl guanidine imaging in rat heart. Ann Nucl Med 2003;17:321-326.
32. Sakata K, Yoshida H, Obayashi K. Comparative effect of cilnidipine and quinapril on left ventricular mass in mild essential hypertension. Drugs Exp Clin Res 2003;29:117-123.
33. Nagai H, Minatoguchi S, Chen XH. Cilnidipine, an N+L-type dihydropyridine Ca channel blocker, suppresses the occurrence of ischemia/reperfusion arrhythmia in a rabbit model of myocardial infarction. Hypertens Res 2005;28:361-368.